1. Home
  2. KLXE vs BOLD Comparison

KLXE vs BOLD Comparison

Compare KLXE & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KLX Energy Services Holdings Inc.

KLXE

KLX Energy Services Holdings Inc.

HOLD

Current Price

$3.73

Market Cap

45.6M

Sector

Energy

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$1.56

Market Cap

36.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
KLXE
BOLD
Founded
2018
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Oilfield Services/Equipment
Sector
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
45.6M
36.5M
IPO Year
2018
2024

Fundamental Metrics

Financial Performance
Metric
KLXE
BOLD
Price
$3.73
$1.56
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
310.4K
402.4K
Earning Date
05-11-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.47
EPS
N/A
N/A
Revenue
$636,600,000.00
N/A
Revenue This Year
$3.89
N/A
Revenue Next Year
$4.95
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.46
$0.96
52 Week High
$3.95
$1.72

Technical Indicators

Market Signals
Indicator
KLXE
BOLD
Relative Strength Index (RSI) 69.08 65.14
Support Level $1.59 $1.08
Resistance Level N/A N/A
Average True Range (ATR) 0.29 0.09
MACD 0.15 -0.01
Stochastic Oscillator 87.64 57.14

Price Performance

Historical Comparison
KLXE
BOLD

About KLXE KLX Energy Services Holdings Inc.

KLX Energy Services Holdings Inc is a growth-oriented provider of diversified oilfield services to onshore oil and natural gas exploration and production (E&P) companies operating in both conventional and unconventional plays in all of the active basins throughout the United States. It serves the companies engaged in the exploration and development of onshore conventional and unconventional oil and natural gas reserves. Its products and services offerings include surface facilities and equipment, pressure control services, wireline services, fishing services, and engineered products. The company's segments include Southwest; Rocky Mountains and Northeast/Mid-Con region. It derives maximum revenue from Southwest region.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: